260 related articles for article (PubMed ID: 8703804)
1. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
4. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
7. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
Bregni M; Siena S; Formosa A; Lappi DA; Martineau D; Malavasi F; Dorken B; Bonadonna G; Gianni AM
Blood; 1989 Feb; 73(3):753-62. PubMed ID: 2465042
[TBL] [Abstract][Full Text] [Related]
8. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Polito L; Bolognesi A; Tazzari PL; Farini V; Lubelli C; Zinzani PL; Ricci F; Stirpe F
Leukemia; 2004 Jul; 18(7):1215-22. PubMed ID: 15103391
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM).
Barbieri L; Dinota A; Gobbi M; Tazzari PL; Rizzi S; Bontadini A; Lemoli RM; Tura S; Stirpe F
Eur J Haematol; 1989 Mar; 42(3):238-45. PubMed ID: 2784390
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
Flavell DJ; Cooper S; Morland B; Flavell SU
Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
Flavell DJ; Boehm DA; Noss A; Flavell SU
Br J Cancer; 1997; 75(7):1035-43. PubMed ID: 9083340
[TBL] [Abstract][Full Text] [Related]
12. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
13. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
[TBL] [Abstract][Full Text] [Related]
14. Selective lesions of rabbit extraocular muscles injected with the anti-AChR immunotoxin saporin-mAb 73.
Campos EC; Schiavi C; Bolognesi A; Bellusci C; Lubelli C; Duca A; Polito L; Poulas K; Tzartos SJ; Stirpe F
Curr Eye Res; 2002 Jan; 24(1):58-65. PubMed ID: 12187496
[TBL] [Abstract][Full Text] [Related]
15. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
16. Selective killing of CD4+ and CD8+ cells with immunotoxins containing saporin.
Barbieri L; Bolognesi A; Dinota A; Lappi DA; Soria M; Tazzari PL; Stirpe F
Scand J Immunol; 1989 Sep; 30(3):369-72. PubMed ID: 2571186
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates.
Siena S; Lappi DA; Bregni M; Formosa A; Villa S; Soria M; Bonadonna G; Gianni AM
Blood; 1988 Aug; 72(2):756-65. PubMed ID: 3042047
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxic activity of ribosome-inactivating protein saporin-6 is attributed to its rRNA N-glycosidase and internucleosomal DNA fragmentation activities.
Bagga S; Seth D; Batra JK
J Biol Chem; 2003 Feb; 278(7):4813-20. PubMed ID: 12466280
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins.
Tecce R; Digiesi G; Savarese A; Trizio D; Natali PG
Int J Cancer; 1993 Aug; 55(1):122-7. PubMed ID: 8102128
[TBL] [Abstract][Full Text] [Related]
20. Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation.
Gosselaar PH; van-Dijk AJ; de-Gast GC; Polito L; Bolognesi A; Vooijs WC; Verheul AF; Krouwer HG; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():61-9. PubMed ID: 11886434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
